Now that the NIH Stem Cell Registry lists more than 160 approved cell lines, we are changing how you address the use of human embryonic stem cells (hESCs) in your application. Beginning with the September 25, 2012 due date and thereafter, you must:
- Specify in your application which hESC line from the NIH Human Embryonic Stem Cell Registry will be used, or
- Provide a strong justification in the Research Strategy section why an unapproved hESC line is needed to complete the research outlined in the application. NOTE: A restricted award will be issued until the specified hESC line(s) is approved and added to the registry.
Unlike before, reviewers will now be asked to evaluate the scientific appropriateness of the chosen hESC line when determining the individual criterion scores, assessments of overall merit, and overall impact scores during initial peer review.
For more information, see NOT-OD-12-111.